Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | FPR2 | P25090 | 11/20 | 0.55 |
| ▸ | CMA1 | P23946 | 2/20 | 0.54 |
| ▸ | FPR1 | P21462 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26606001 | 0.88 | CA12 (0.61) | CA12CA1CA2CA9FPR2 | |
| SCHEMBL26606003 | 0.88 | CA12 (0.61) | CA12CA1CA2CA9FPR2 | |
| SCHEMBL8214118 | 0.83 | CA12 (0.58) | CA12CA1CA2CA9FPR2 | |
| SCHEMBL6021330 | 0.83 | CTSS (0.64) | FPR2FPR1 | |
| SCHEMBL6020284 | 0.81 | FPR2 (0.51) | FPR2FPR1 | |
| SCHEMBL12149993 | 0.81 | POLB (0.63) | — | |
| SCHEMBL21428974 | 0.81 | CTSG (0.52) | CTSGCMA1 | |
| SCHEMBL4422603 | 0.81 | F7 (0.61) | CA12CA1CA2CA9FPR2 | |
| SCHEMBL5178675 | 0.79 | CTSG (0.52) | CTSGCMA1 | |
| SCHEMBL7611756 | 0.79 | CTSG (0.52) | CTSGCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299354-B1 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-6743790-B2 | A UREA OR THIOUREA DERIVATIVES CONTAINING AMIDE GROUP USEFUL AS ANTICOAGULANTS AND ANTIINFLAMMATORY AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-01 | — | — | US | disclosed |
| EP-1299354-A2 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | Aventis Pharma Deutschland GmbH (DE) | 2003-04-09 | — | — | EP | disclosed |
| US-20020052417-A1 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-05-02 | — | — | US | disclosed |
| WO-2001094301-A2 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-13 | — | — | WO | disclosed |
| EP-1162194-A1 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use | Aventis Pharma Deutschland GmbH (DE) | 2001-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052417-A1 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use | F7, F9, F5 | CTSG 1443/4885CA12 4382/4885CA1 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.